Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juliana Delgado Campos Mello has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Lívia Moreira Genaro

    Universidade Estadual de Campinas (UNICAMP), Faculdade de Ciências Médicas (FCM), Surgery Department, Gastrocenter, Colorectal Surgery Unit, Inflammatory Bowel Disease Research Laboratory (LABDII), Campinas, SP, Brazil

    3 shared publications
  • Raquel Franco Leal

    Inflammatory Bowel Disease Research Laboratory, Gastrocenter, Colorectal Surgery Unit, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil

    3 shared publications
  • Adrieli Heloísa Campardo Pansani

    Inflammatory Bowel Disease Research Laboratory, Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas (Unicamp), Campinas 13083-878, SP, Brazil

    1 shared publication
  • Ana Emília Carvalho de Paula

    Health Sciences Institute, Federal University of Jatai (UFJ), Jataí, Brazil

    1 shared publication
  • Ana Paula Menezes de Freitas Franceschini

    Inflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas (Unicamp), Campinas, São Paulo, Brazil

    1 shared publication
  • Carmen Silvia Passos Lima

    Laboratory of Cancer Genetics (Lageca), School of Medical Sciences, University of Campinas (Unicamp), Campinas, São Paulo, Brazil

    1 shared publication

Latest Publications

  • Open Access

    Ileocolic resection versus medical therapy for Crohn’s disease in the post-biologic era: a systematic review

    by Nicole Compagnoni Gallina, Lívia Moreira Genaro, Juliana Delgado Campos Mello, Leandro Minatel Vidal de Negreiros, Maria de Lourdes Setsuko Ayrizono, Raquel Franco Leal

    Crohn’s disease (CD) is a chronic, idiopathic inflammatory bowel condition with increasing incidence globally. For a long time, the treatment for ileal disease relied on surgery for complications or refractoriness to conventional clinical management. With the advent of immunobiological agents, the natural history of the disease has been altered, establishing a new treatment paradigm. This study aimed to perform a systematic review (SR) depicting the role of surgical resection in the post-biological era, especially as initial therapy for limited disease. A comprehensive search of PubMed, PubMed PMC, BVS/BIREME, CINAHL, Web of Science, Embase, Cochrane Library, and ProQuest databases was performed, including studies published up to July 2025. Six retrospective and two prospective studies were included, all developed in Europe, except for one in Canada. Only one included a pediatric population. Of the eight studies, two directly compared ileocolic resection with biological therapy. The remaining studies assessed only surgical outcomes. Five studies evaluated complications after surgical treatment and one after medical treatment, with median rates of 10% and 3%, respectively. Five studies analyzed clinical remission rates, and five assessed endoscopic remission at varying follow-up times. At approximately 1 year of follow-up, endoscopic remission rates ranged from 29% to 79% in the surgical group and from 48% to 84% in the biologics group. Clinical remission was assessed only in the surgical group, with rates of 60%, 83.7%, and 92% at 1 year, and 74% and 88% at 10 years. In the direct comparison of surgery versus biological therapy, only one study evaluated the subsequent need for additional biological treatment during follow-up, and this need was similar among the groups. Ileocolectomy is an effective and viable therapeutic alternative to primary biological therapy for localized and refractory ileal CD. Early surgery can offer more sustained control for specific phenotypes, reducing the need for long-term treatment. The decision should be individualized, taking into account risks, disease phenotype, and patient preferences. Further randomized trials are needed to refine recommendations.

  • Open Access

    Prognostic Value of Enterography Findings in Crohn’s Disease: A Systematic Review and Meta-Analysis

    by Felipe Montevechi-Luz, Adrieli Heloísa Campardo Pansani, Juliana Delgado Campos Mello, Ana Emilia Carvalho de Paula, Lívia Moreira Genaro, Marcia Carolina Mazzaro, Daniel Lahan-Martins, Raquel Franco Leal

    Crohn’s disease is a chronic inflammatory disorder with variable progression that often leads to hospitalization, treatment escalation, or surgery. While clinical and endoscopic indices guide disease monitoring, cross-sectional enterography provides unique visualization of transmural and extramural inflammation, offering valuable prognostic information. This systematic review and meta-analysis examined the prognostic significance of magnetic resonance enterography (MRE) and computed tomography enterography (CTE) in Crohn’s disease. Following PRISMA guidelines and a registered protocol, eight databases were systematically searched through August 2024. Two reviewers independently conducted data extraction, risk-of-bias assessment (QUADAS-2), and certainty grading (GRADE). Random-effects models were applied for pooled analyses. Eleven studies, including more than 1500 patients, met eligibility criteria. Across cohorts, transmural healing on enterography was consistently associated with favorable long-term outcomes, including a markedly lower need for surgery and hospitalization. Conversely, stenosis and persistent inflammatory activity identified patients at substantially higher risk of surgery, treatment intensification, or disease-related hospitalization. The certainty of evidence was high for surgical outcomes and moderate to low for other endpoints. Conventional enterography provides meaningful prognostic insight into Crohn’s disease and should be considered a complementary tool for risk stratification and treatment planning. Transmural healing represents a protective marker of a favorable disease course, whereas structural and inflammatory findings indicate patients who may benefit from closer monitoring or earlier therapeutic intervention.


  • Open Access

    Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn’s disease patients

    by Livia Moreira Genaro, Juliana Carron, Marina Moreira de Castro, Ana Paula Menezes de Freitas Franceschini, Gustavo Jacob Lourenço, Cristiane Kibune Nagasako Vieira da Cruz, Glaucia Fernanda Soares Rupert Reis, Livia Bitencourt Pascoal, Juliana Delgado Campos Mello, Isabela Machado Pereira, et al.

    Crohn’s disease (CD) involves immune system interactions with intestinal tissue, driven by pro-inflammatory cytokines like Tumor Necrosis Factor (TNF-α). Adalimumab, targeting TNF-α, regulates associated inflammatory responses. Despite being humanized, it may induce immunogenic processes, affecting treatment effectiveness. Thus, monitoring serum adalimumab and anti-drug antibody (ADA) levels can optimize therapy. Understanding genetic factors influencing adalimumab response can enhance personalized treatment and improve patient quality of life. We aimed to quantify adalimumab serum levels, assess test interchangeability, detect ADA, examine immune complex formation, and investigate genetic phenotypes related to immunogenicity in CD patients. Seventy CD patients in the maintenance phase with adalimumab were classified into active (CDA) and remission (CDR) groups. Adalimumab concentration was determined via enzyme-linked immunosorbent assay (ELISA—Promonitor) and lateral flow assay (Quantum Blue), with assay interchangeability assessed statistically. ADA and immune complex formation were quantified using ELISA assays. DNA was genotyped for the genes ATG16L1, CD96, and CD155. No significant differences in adalimumab serum concentrations were observed between groups, regardless of the assay. However, a statistical difference between the tests indicated measurement disparity ( P = 0.003), with moderate agreement (Lin’s correlation of 0.247). ADA was detected in 4 of 27 of the patients with infratherapeutic levels, 3 in the CDA group and 1 in the CDR group. Analysis of immune complexes revealed significantly higher concentrations in the CDA group ( P = 0.0125). The genotypic evaluation revealed significant associations for the CD96 CC (wild-type) genotype with higher CRP levels, colonic involvement, and infratherapeutic levels of adalimumab. ATG16L1 CC genotype was associated with higher CDEIS and fecal calprotectin values, while the variant (TT) genotype had lower platelet counts. The effectiveness of treatment with adalimumab was not directly related to higher medication levels in this cohort. The disparity between tests indicates the need to use only one test in patient follow-up to ensure accuracy in therapeutic monitoring. Genotypic differences highlight the correlation between the wild genotype for CD96 and ATG16L1 with unfavorable laboratory and endoscopic response to adalimumab. Finally, the more significant levels of immune complexes in the CDA group indicate an association with a worse response to adalimumab.